$TGTX
TG THERAPEUTICS, INC.

2020 Q4 Form 10-Q Financial Statement

#000155837020013410 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $40.00K $38.00K $38.00K
YoY Change 0.0% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $43.86M $35.30M $2.910M
YoY Change 521.25% 1112.92% 200.0%
% of Gross Profit
Research & Development $42.96M $50.46M $57.99M
YoY Change 38.85% -12.97% 73.62%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $20.00K
YoY Change 66.67% 150.0% 0.0%
% of Gross Profit
Operating Expenses $86.82M $85.76M $60.90M
YoY Change 128.49% 40.82% 77.21%
Operating Profit -$85.72M -$60.86M
YoY Change 40.85% 77.29%
Interest Expense -$1.290M $1.610M $1.537M
YoY Change -32.11% 4.75% 595.48%
% of Operating Profit
Other Income/Expense, Net -$150.0K -$1.441M -$1.069M
YoY Change -151.72% 34.8% 183.55%
Pretax Income -$88.22M -$87.16M -$61.93M
YoY Change 122.95% 40.74% 82.42%
Income Tax
% Of Pretax Income
Net Earnings -$88.22M -$87.16M -$61.93M
YoY Change 122.94% 40.74% 82.41%
Net Earnings / Revenue -220550.0% -229376.32% -162973.68%
Basic Earnings Per Share
Diluted Earnings Per Share -$710.4K -$731.3K -$690.6K
COMMON SHARES
Basic Shares Outstanding 131.5M 126.6M 94.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $605.4M $254.2M $72.50M
YoY Change 331.2% 250.62% -25.79%
Cash & Equivalents $553.4M $254.2M $44.68M
Short-Term Investments $52.00M $0.00 $27.80M
Other Short-Term Assets $1.083M $641.0K $864.0K
YoY Change 77.25% -25.81% -92.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $611.7M $260.3M $80.36M
YoY Change 310.15% 223.98% -26.75%
LONG-TERM ASSETS
Property, Plant & Equipment $481.0K $378.0K $275.0K
YoY Change 70.57% 37.45% -89.42%
Goodwill $799.0K $799.0K $799.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $1.300M $1.200M
YoY Change 0.0% 8.33% 0.0%
Total Long-Term Assets $13.90M $13.52M $12.97M
YoY Change 0.28% 4.23% 176.0%
TOTAL ASSETS
Total Short-Term Assets $611.7M $260.3M $80.36M
Total Long-Term Assets $13.90M $13.52M $12.97M
Total Assets $625.6M $273.9M $93.33M
YoY Change 283.8% 193.44% -18.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $37.00M $34.70M $31.80M
YoY Change 23.33% 9.12% -16.09%
Accrued Expenses $10.10M $6.700M $4.400M
YoY Change 87.04% 52.27% 109.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $22.18M $14.59M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $87.55M $77.67M $80.20M
YoY Change 3.68% -3.15% 99.5%
LONG-TERM LIABILITIES
Long-Term Debt $7.716M $15.07M $28.74M
YoY Change -73.37% -47.55%
Other Long-Term Liabilities $11.00M $10.50M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $7.716M $15.07M $28.74M
YoY Change -73.37% -47.55% 1097.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $87.55M $77.67M $80.20M
Total Long-Term Liabilities $7.716M $15.07M $28.74M
Total Liabilities $106.3M $103.2M $119.1M
YoY Change -14.56% -13.36% 179.62%
SHAREHOLDERS EQUITY
Retained Earnings -$980.6M -$892.4M -$661.6M
YoY Change 39.84% 34.88%
Common Stock $141.0K $129.0K $97.00K
YoY Change 29.36% 32.99%
Preferred Stock
YoY Change
Treasury Stock (at cost) $200.0K $234.0K $234.0K
YoY Change -14.53% 0.0%
Treasury Stock Shares $41.31K $41.31K 41.31K shares
Shareholders Equity $519.4M $170.7M -$25.80M
YoY Change
Total Liabilities & Shareholders Equity $625.6M $273.9M $93.33M
YoY Change 283.8% 193.44% -18.42%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$88.22M -$87.16M -$61.93M
YoY Change 122.94% 40.74% 82.41%
Depreciation, Depletion And Amortization $50.00K $50.00K $20.00K
YoY Change 66.67% 150.0% 0.0%
Cash From Operating Activities -$52.03M -$56.53M -$33.20M
YoY Change 71.15% 70.27% 0.58%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K -$90.00K -$70.00K
YoY Change 433.33% 28.57% 250.0%
Acquisitions
YoY Change
Other Investing Activities -$51.92M $15.00M $20.00K
YoY Change -129900.0% 74900.0% -100.31%
Cash From Investing Activities -$52.08M $14.91M -$40.00K
YoY Change -37375.0% -99.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 403.4M 35.27M 20.70M
YoY Change 310.16% 70.39% 360.0%
NET CHANGE
Cash From Operating Activities -52.03M -56.53M -33.20M
Cash From Investing Activities -52.08M 14.91M -40.00K
Cash From Financing Activities 403.4M 35.27M 20.70M
Net Change In Cash 299.3M -6.350M -12.54M
YoY Change 340.44% -49.36% -64.12%
FREE CASH FLOW
Cash From Operating Activities -$52.03M -$56.53M -$33.20M
Capital Expenditures -$160.0K -$90.00K -$70.00K
Free Cash Flow -$51.87M -$56.44M -$33.13M
YoY Change 70.79% 70.36% 0.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001001316
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32639
dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street, 9th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
554-4484
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TGTX
dei Trading Symbol
TradingSymbol
TGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131490195
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254154000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
27798000
CY2020Q3 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
5540000
CY2019Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
8105000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
641000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
611000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
260335000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
149151000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1257000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1251000
CY2020Q3 tgtx Leasehold Interest
LeaseholdInterest
2104000
CY2019Q4 tgtx Leasehold Interest
LeaseholdInterest
2129000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
378000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
282000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8983000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9402000
CY2020Q3 us-gaap Goodwill
Goodwill
799000
CY2019Q4 us-gaap Goodwill
Goodwill
799000
CY2020Q3 us-gaap Assets
Assets
273856000
CY2019Q4 us-gaap Assets
Assets
163014000
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34659000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
30041000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21735000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48994000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
14590000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1614000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1616000
CY2020Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
5072000
CY2019Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
3798000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
77670000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
84449000
CY2020Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
648000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
762000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15074000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28970000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9806000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10218000
CY2020Q3 us-gaap Liabilities
Liabilities
103198000
CY2019Q4 us-gaap Liabilities
Liabilities
124399000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128959861
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109425243
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128918552
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109383934
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
129000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
109000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1063142000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
739956000
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-892379000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-701216000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
170658000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
273856000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
163014000
CY2020Q3 us-gaap Revenues
Revenues
38000
CY2019Q3 us-gaap Revenues
Revenues
38000
us-gaap Revenues
Revenues
114000
us-gaap Revenues
Revenues
114000
tgtx Non Cash Stock Expense Associated With In Licensing Agreements
NonCashStockExpenseAssociatedWithInLicensingAgreements
100000
CY2020Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
4618000
CY2019Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
1482000
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
8150000
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
4323000
CY2020Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
45846000
CY2019Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
56503000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
114785000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
118814000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50464000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57985000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122935000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
123237000
CY2020Q3 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
23712000
CY2019Q3 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
593000
tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
38618000
tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
1391000
CY2020Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
11584000
CY2019Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
2321000
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
25373000
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
6580000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35296000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2914000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
63991000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7971000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
85760000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
60899000
us-gaap Operating Expenses
OperatingExpenses
186926000
us-gaap Interest Expense
InterestExpense
3388000
CY2020Q3 us-gaap Other Income
OtherIncome
169000
CY2019Q3 us-gaap Other Income
OtherIncome
468000
us-gaap Other Income
OtherIncome
687000
us-gaap Other Income
OtherIncome
1183000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1441000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1069000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.55
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
119176336
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89667979
us-gaap Operating Expenses
OperatingExpenses
131208000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-85722000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60861000
us-gaap Operating Income Loss
OperatingIncomeLoss
-186812000
us-gaap Operating Income Loss
OperatingIncomeLoss
-131094000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1610000
CY2019Q3 us-gaap Interest Expense
InterestExpense
1537000
us-gaap Interest Expense
InterestExpense
5038000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4351000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2205000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-87163000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-61930000
us-gaap Profit Loss
ProfitLoss
-191163000
us-gaap Profit Loss
ProfitLoss
-133299000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.70
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
112380784
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85911878
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24036000
CY2019Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
993000
CY2019Q1 tgtx Offering Costs At Market
OfferingCostsAtMarket
200000
CY2019Q1 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
27499000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1882000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-35156000
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19254000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11000
CY2019Q2 tgtx Offering Costs At Market
OfferingCostsAtMarket
500000
CY2019Q2 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
28395000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1757000
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-36212000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13205000
CY2019Q3 tgtx Offering Costs At Market
OfferingCostsAtMarket
400000
CY2019Q3 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
20759000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2075000
CY2019Q3 tgtx Stock Issued During Period Value In Licensing Agreements
StockIssuedDuringPeriodValueInLicensingAgreements
100000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-61930000
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-25791000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2020Q2 tgtx Offering Costs At Market
OfferingCostsAtMarket
1400000
CY2020Q2 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
76036000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7370000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-52884000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
194227000
us-gaap Profit Loss
ProfitLoss
-191163000
us-gaap Profit Loss
ProfitLoss
-133299000
us-gaap Share Based Compensation
ShareBasedCompensation
46768000
us-gaap Share Based Compensation
ShareBasedCompensation
5714000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11068000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-51116000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1353000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2020Q2 tgtx Offering Costs
OfferingCosts
10900000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
165042000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2020Q3 tgtx Offering Costs
OfferingCosts
10900000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-1000
CY2020Q3 tgtx Offering Costs At Market
OfferingCostsAtMarket
2000000.0
CY2020Q3 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
35227000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
28330000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-87163000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
170658000
tgtx Noncash Licensing Expense
NoncashLicensingExpense
100000
us-gaap Depreciation
Depreciation
105000
us-gaap Depreciation
Depreciation
72000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
75000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
209000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
694000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
539000
us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
163000
us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
137000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1364000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1921000
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-286000
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-28000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2398000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2226000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-105000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
5893000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-3837000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1360000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1129000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
238000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
787000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-27783000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
24651000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-162481000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102413000
tgtx Proceeds From Maturities
ProceedsFromMaturities
35250000
tgtx Proceeds From Maturities
ProceedsFromMaturities
22500000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
23125000
tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
7482000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
202000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
97000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27566000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-722000
tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
276303000
tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
76664000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
135000
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
29675000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
480000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
276438000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105859000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
141523000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2724000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43199000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255411000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45923000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254154000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44675000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
1257000
CY2019Q3 us-gaap Restricted Cash
RestrictedCash
1248000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255411000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45923000
us-gaap Interest Paid Net
InterestPaidNet
3447000
us-gaap Interest Paid Net
InterestPaidNet
1837000
tgtx Accrued Financing Costs
AccruedFinancingCosts
988000
tgtx Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
993000
tgtx Shares Issued In Connection With In Licensing Agreements Value
SharesIssuedInConnectionWithInLicensingAgreementsValue
100000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-892400000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
254200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p>
CY2020Q3 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2019Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>
CY2020Q3 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
5500000
CY2019Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
8100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11103701
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11103701
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8060758
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8060758
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11103701
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8060758
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Cash
Cash
223613000
CY2019Q4 us-gaap Cash
Cash
110135000
CY2020Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
30541000
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2502000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254154000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
0
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
27798000
CY2019Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
28000
CY2019Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
0
CY2019Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
27826000
CY2020Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
477000
CY2020Q3 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
477000
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
190000
CY2019Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
190000
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
190000
tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
730000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-443000
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
477000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.8691
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.7299
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0196
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
27520000
us-gaap Restricted Stock Expense
RestrictedStockExpense
41615000
CY2020Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
810000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
5153000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
28330000
us-gaap Share Based Compensation
ShareBasedCompensation
46768000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
147058
CY2019Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
4.08
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1032347000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
0
tgtx Warrant Or Right Issued Weighted Average Exercise Price
WarrantOrRightIssuedWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0
tgtx Warrant Or Right Exercised Weighted Average Exercise Price
WarrantOrRightExercisedWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0
tgtx Warrant Or Right Expired Weighted Average Exercise Price
WarrantOrRightExpiredWeightedAverageExercisePrice
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
147058
CY2020Q3 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
4.08
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
3335275000
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
477000
CY2020Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2020Q3 us-gaap Notes Payable
NotesPayable
477000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
190000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2019Q4 us-gaap Notes Payable
NotesPayable
190000
tgtx Cumulative Liability Of Note
CumulativeLiabilityOfNote
20000000.0
CY2019 tgtx Cumulative Liability Of Note
CumulativeLiabilityOfNote
19300000
tgtx Agreement Costs Aggregate
AgreementCostsAggregate
53400000
CY2020Q3 us-gaap Construction Contract Cost Progress Payment Offset
ConstructionContractCostProgressPaymentOffset
33200000
tgtx Agreement Costs Current Liabilities
AgreementCostsCurrentLiabilities
19400000
tgtx Agreement Costs Non Current Liabilities
AgreementCostsNonCurrentLiabilities
0
tgtx Percentage Of Administrative Fee
PercentageOfAdministrativeFee
0.06
tgtx Interest Expense Recognized As Administrative Fees
InterestExpenseRecognizedAsAdministrativeFees
2600000
CY2020Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
30000000
CY2020Q3 tgtx End Of Term Fee
EndOfTermFee
975000
CY2020Q3 tgtx Long Term Debt Gross
LongTermDebtGross
30975000
CY2020Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1311000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
29664000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
14590000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15074000
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
534000
us-gaap Operating Lease Cost
OperatingLeaseCost
1611000
CY2020Q3 us-gaap Lease Cost
LeaseCost
534000
us-gaap Lease Cost
LeaseCost
1611000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1614000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9806000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11420000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
475000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1889000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1911000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1914000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1797000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10618000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18604000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7184000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11420000

Files In Submission

Name View Source Status
0001558370-20-013410-index-headers.html Edgar Link pending
0001558370-20-013410-index.html Edgar Link pending
0001558370-20-013410.txt Edgar Link pending
0001558370-20-013410-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20200930.xsd Edgar Link pending
tgtx-20200930x10q.htm Edgar Link pending
tgtx-20200930x10q_htm.xml Edgar Link completed
tgtx-20200930xex31d1.htm Edgar Link pending
tgtx-20200930xex31d2.htm Edgar Link pending
tgtx-20200930xex32d1.htm Edgar Link pending
tgtx-20200930xex32d2.htm Edgar Link pending
tgtx-20200930_cal.xml Edgar Link unprocessable
tgtx-20200930_def.xml Edgar Link unprocessable
tgtx-20200930_lab.xml Edgar Link unprocessable
tgtx-20200930_pre.xml Edgar Link unprocessable